The mammalian chromosomes present specific sites of gaps or breaks, the common fragile sites (CFSs), when the cells are exposed to DNA replication stress or to some DNA binding compounds. CFSs span hundreds or thousands of kilobases. The analysis of these sequences has not definitively clarified the causes of their fragility. There is considerable evidence that CFSs are regions of late or slowed replication in the presence of sequence elements that have the propensity to form secondary structures, and that the cytogenetic expression of CFSs may be due to unreplicated DNA. In order to analyse the relationship between DNA replication time and fragility, in this work we have investigated the timing of replication of sequences mapping within two CFSs (FRA1H and FRA2G), of syntenic non-fragile sequences and of early and late replicating control sequences by using fluorescent in situ hybridization on interphase nuclei, conventional fluorescence microscopy and confocal microscopy. Our results indicate that the fragile sequences are slow replicating and that they enter G2 phase unreplicated with very high frequency. Thus these regions could sometimes reach mitosis unreplicated or undercondensed and be expressed as chromosome gaps/breakages.

1.
Artl MF, Casper AM, Glover TW: Common fragile sites. Cytogenet Genome Res 100:92–100 (2003).
2.
Artl MF, Xu B, Durkin SD, Casper AM, Kastan MB, Glover TW: BRCA1 is required for common-fragile-site stability via its G2/M checkpoint function. Mol Cell Biol 24:6701–6709 (2004).
3.
Casper AM, Nghiem P, Artl MF, Glover TW: ATR regulates fragile site stability. Cell 111:779–789 (2002).
4.
Curatolo A, Limongi ZM, Pelliccia F, Rocchi A: Molecular characterization of the human common fragile site FRA1H. Genes Chromosomes Cancer 46:487–493 (2007).
5.
D’Urso G, Grallert B, Nurse P: DNA polymerase alpha, a component of the replication initiation complex, is essential for the checkpoint coupling S phase to mitosis in fission yeast. J Cell Sci 108:3109–3118 (1995).
6.
Fitzgerald DJ, Anderson JN: Selective nucleosome disruption by drugs that bind in the minor groove of DNA. J Biol Chem 274:27128–27138 (1999).
7.
Glover TW, Artl MF, Casper AM, Durkin SG: Mechanisms of common fragile site instability. Hum Mol Genet 14:R197–R205 (2005).
8.
Handt O, Baker E, Dayan S, Gartler SM, Woollatt E, et al: Analysis of replication timing at the FRA10B and FRA16B fragile site loci. Chromosome Res 8:677–688 (2000).
9.
Hansen RS, Canfield TK, Field AD, Mumm S, Laird CD, Gartler SM: A variable domain of delayed replication in FRAXA fragile X chromosomes: X inactivation-like spread of late replication. Proc Natl Acad Sci USA 94:4587–4592 (1997).
10.
Hellman A, Rahat A, Scherer SW, Darvasi A, Tsui LC, Kerem B: Replication delay along FRA7H, a common fragile site on human chromosome 7, leads to chromosomal instability. Mol Cell Biol 20:4420–4427 (2000).
11.
Labib K, Hodgson B: Replication fork barriers: pausing for a break or stalling for time? EMBO Rep 8:346–353 (2007).
12.
Laird C, Jaffe E, Karpen G, Lamb M, Nelson R: Fragile sites in human chromosomes as regions of late-replicating DNA. Trends Genet 3:274–281 (1987).
13.
Le Beau MM, Rassool FV, Neilly ME, Espinosa R 3rd, Glover TW, et al: Replication of a common fragile site, FRA3B, occurs late in S phase and is delayed further upon induction: implications for the mechanism of fragile site induction. Hum Mol Genet 7:755–761 (1998).
14.
Limongi MZ, Pelliccia F, Rocchi A: Characterization of the human common fragile site FRA2G. Genomics 81:93–97 (2003).
15.
Mitelman F, Johansson B, Mertens F (eds): Mitelman Database of Chromosome Aberrations in Cancer. http://cgap.nci.nih.gov/Chromosomes/Mitelman (2007).
16.
Morley BJ, Abbott CA, Wood WG: Regulation of human fetal and adult globin genes in mouse erythroleukemia cells. Blood 78:1355–1363 (1991).
17.
O’Keefe RT, Henderson SC, Spector DL: Dynamic organization of DNA replication in mammalian cell nuclei: spatially and temporally defined replication of chromosome-specific alpha-satellite DNA sequences. J Cell Biol 116:1095–1110 (1992).
18.
Palakodeti A, Han Y, Jiang Y, Le Beau MM: The role of late/slow replication of the FRA16D in common fragile site induction. Genes Chromosomes Cancer 39:71–76 (2004).
19.
Prantera G, Di Castro M, Cipriani L, Rocchi A: Inhibition of human chromosome condensation induced by DAPI as related to cell cycle. Exp Cell Res 135:63–68 (1981).
20.
Sadoni N, Langer S, Fauth C, Bernardi G, Cremer T, et al: Nuclear organization of mammalian genomes: polar chromosome territories build up functionally distinct higher order compartments. J Cell Biol 146:1211–1226 (1999).
21.
Selig S, Okumura K, Ward DC, Cedar H: Delineation of DNA replication time zones by fluorescence in situ hybridization. EMBO J 11:1217–1225 (1992).
22.
Smith ZE, Higgs DR: The pattern of replication at a human telomeric region (16p13.3): its relationship to chromosome structure and gene expression. Hum Mol Genet 8:1373–1386 (1999).
23.
Subramanian PS, Nelson DL, Chinault AC: Large domains of apparent delayed replication timing associated with triplet repeat expansion at FRAXA and FRAXE. Am J Hum Genet 59:407–416 (1996).
24.
Sutherland GR, Baker E, Richards RI: Fragile sites still breaking. Trends Genet 14:501–506 (1998).
25.
Widrow RJ, Hansen RS, Kawame H, Gartler SM, Laird CD: Very late DNA replication in the human cell cycle. Proc Natl Acad Sci USA 95:11246–11250 (1998).
26.
Zlotorynski E, Rahat A, Skaug J, Ben-Porat N, Ozeri E, et al: Molecular basis for expression of common and rare fragile sites. Mol Cell Biol 23:7143–7151 (2003).
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.